On June 4, 2025, NewAmsterdam Pharma Co N.V. held its annual general meeting where shareholders approved several proposals including financial accounts from 2024, director discharges, and auditor appointments, with significant participation (about 74.45%). Additionally, the company decided on annual advisory votes for executive pay going forward.